Previous Close | 2.8400 |
Open | 2.8500 |
Bid | 2.9500 x 800 |
Ask | 2.9600 x 800 |
Day's Range | 2.8100 - 3.0000 |
52 Week Range | 2.8050 - 34.1250 |
Volume | |
Avg. Volume | 3,046,923 |
Market Cap | 86.335M |
Beta (5Y Monthly) | 0.99 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -6.8700 |
Earnings Date | Nov 08, 2023 - Nov 13, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 19.50 |
Subscribe to Yahoo Finance Plus to view Fair Value for BTAI
In this piece, we will take a look at the 16 most shorted stocks right now. If you want to skip our introduction to short selling, then take a look at 5 Most Shorted Stocks Right Now. One of the most intriguing plays on the stock market is short selling. This is because it goes […]
By David Bautz, PhD NASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT Business Update Strategic Reprioritization Underway On August 14, 2023, BioXcel Therapeutics, Inc. (NASDAQ:BTAI) announced a strategic reprioritization that will impact a number of the areas of the business, including: • The commercial strategy for IGALMI will shift to focus more on the retail pharmacy and at-home setting and away
After the biotech's share price tanked on Monday on the back of less-than-inspiring quarterly results and the announcement of significant job cuts, it was hammered again the following day. As often happens in the wake of quarterly earnings reports that are either far better or substantially worse than expected, analysts adjusted their takes on BioXcel Tuesday. One prognosticator, Graig Suvannavejh of Mizuho Securities, went as far as to downgrade his recommendation on the stock.